E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).

被引：1
|
作者：
Argiris, A.
Lee, J.
Schiller, J. H.
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps221
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS221
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
    Laslett, Nicole F.
    Park, Sujung
    Masters, Gregory A.
    Biggs, David D.
    Schneider, Charles J.
    Misleh, Jamal G.
    Suppiah, Kathir
    Simpson, Pamela S.
    Grubbs, Stephen
    Wozniak, Timothy F.
    Guarino, Michael
    CANCER MEDICINE, 2018, 7 (07): : 2969 - 2973
  • [42] Randomized, phase II trial comparing carboplatin (C) and tri-weekly paclitaxel (tP) with C and weekly paclitaxel (wP) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Maemondo, M.
    Inoue, A.
    Sugawara, S.
    Ishida, T.
    Usui, K.
    Abe, T.
    Kanbe, M.
    Watanabe, H.
    Saijo, Y.
    Nukiwa, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer SWOG S0536
    Kim, Edward S.
    Moon, James
    Herbst, Roy S.
    Redman, Mary W.
    Dakhil, Shaker R.
    Velasco, Mario R., Jr.
    Hirsch, Fred R.
    Mack, Philip C.
    Kelly, Karen
    Heymach, John V.
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1519 - 1528
  • [45] A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Blumenschein, GR
    Khuri, F
    Gatzemeier, U
    Miller, WH
    von Pawel, J
    Rigas, JR
    Herbst, RS
    Dziewanowska, Z
    Negro-Vilar, A
    Mabry, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1094S - 1094S
  • [46] Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
    Hirsh, V.
    Boyer, M.
    Rosell, R.
    Benner, R. J.
    Readett, D.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A randomized Phase II trial of the tumor vascular disrupting agent CACA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
    Garon, Edward B.
    Neidhart, Jeffrey D.
    Gabrail, Nashat Y.
    de Oliveira, Moacyr R.
    Balkissoon, Jai
    Kabbinavar, Fairooz
    ONCOTARGETS AND THERAPY, 2016, 9 : 7275 - 7283
  • [48] Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients
    Schmittel, A
    Siehl, JM
    Schulze, M
    Schulze, K
    Thiel, E
    Keilholz, U
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1333 - 1336
  • [49] Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)
    Thomas, M.
    Reuss, A.
    Fischer, J. R.
    Andreas, S.
    Kortsik, C.
    Grah, C.
    Serke, M. H.
    von Eiff, M.
    Witt, C.
    Kollmeier, J.
    Mueller, E.
    Mueller, L.
    Schenk, M.
    Heine, R.
    Behringer, D. M.
    Schroeder, M.
    Reinmuth, N.
    Schnabel, P.
    Acker, T.
    Wolf, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Phase II Trial of Carboplatin, Pemetrexed, Bevacizumab in Advanced non-Small Cell (non-Squamous) Lung Cancer
    Guarino, Michael J.
    Masters, Gregory A.
    Biggs, David D.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S698 - S698
12345